Taken together, the genetic (knockdown/overexpression), pharmacologic (BCI-121), and chromatin (ChIP) evidence demonstrate that CDCP1 is a direct chromatin target of SMYD3 in colorectal cancer cells. This evidence concerns the gene SMYD3 and colorectal cancer.